Duygu Metin
Duygu Metin has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Hamide Piskinpasa
Department of Endocrinology and Metabolism, Bakırköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences Türkiye, 34147 Istanbul, Türkiye
3 shared publications - Evin Bozkur
Bakırkoy Dr Sadi Konuk Training and Research Hospital, University of Health Sciences , Istanbul , Türkiye
2 shared publications - İlKay Cakir
Department of Endocrinology and Metabolism, University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
2 shared publications - Meral Mert
Endocrinology Clinic, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Health Sciences University, 34147 İstanbul, Türkiye
2 shared publications - Naim Pamuk
Department of Endocrinology and Metabolism, Bakırköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences Türkiye, 34147 Istanbul, Türkiye
2 shared publications - Nuri Alper Sahbaz
Department of General Surgery, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
2 shared publications
Latest Publications
- 14 October 2022
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 84 (1) , 8-13
The significance of forearm bone mineral density evaluation in determining surgical indications in primary hyperparathyroidism
- 14 October 2022
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 84 (1) , 8-13
The significance of forearm bone mineral density evaluation in determining surgical indications in primary hyperparathyroidism
- Open Access
- 11 October 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (1) , 45-54
The effect of COVID-19 process on patients with endocrinological disease in a pandemic hospital: What happened to the others?
Objective: To evaluate the effects of the pandemic process on those with an endocrinological disease that will require close follow-up from the last visit before the pandemic. Materials and methods: Patients of 3,903 with thyroid, calcium-bone metabolism, adrenal gland, pituitary diseases, and neuroendocrine tumor (NET) were retrospectively scanned. The remaining 855 (656 females and 199 males) patients with active disease or who still needed multidisciplinary approaches were included. The number of patients who continued the disease-related medical procedures and [...] ABSTRACT Objective: To evaluate the effects of the pandemic process on those with an endocrinological disease that will require close follow-up from the last visit before the pandemic. Materials and methods: Patients of 3,903 with thyroid, calcium-bone metabolism, adrenal gland, pituitary diseases, and neuroendocrine tumor (NET) were retrospectively scanned. The remaining 855 (656 females and 199 males) patients with active disease or who still needed multidisciplinary approaches were included. The number of patients who continued the disease-related medical procedures and
- 11 October 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (1) , 45-54
Open AccessThe effect of COVID-19 process on patients with endocrinological disease in a pandemic hospital: What happened to the others?
Objective: To evaluate the effects of the pandemic process on those with an endocrinological disease that will require close follow-up from the last visit before the pandemic. Materials and methods: Patients of 3,903 with thyroid, calcium-bone metabolism, adrenal gland, pituitary diseases, and neuroendocrine tumor (NET) were retrospectively scanned. The remaining 855 (656 females and 199 males) patients with active disease or who still needed multidisciplinary approaches were included. The number of patients who continued the disease-related medical procedures and [...] ABSTRACT Objective: To evaluate the effects of the pandemic process on those with an endocrinological disease that will require close follow-up from the last visit before the pandemic. Materials and methods: Patients of 3,903 with thyroid, calcium-bone metabolism, adrenal gland, pituitary diseases, and neuroendocrine tumor (NET) were retrospectively scanned. The remaining 855 (656 females and 199 males) patients with active disease or who still needed multidisciplinary approaches were included. The number of patients who continued the disease-related medical procedures and
- Open Access
- 17 March 2022
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 47 (4) , 457-463
The correlation between bone biomarkers, glucosylsphingosine levels, and molecular findings in Gaucher type 1 patients under enzyme therapy
Objectives: We aimed to determine the relationship of Lyso-Gb1 levels, bone biomarkers, and mutation findings with bone marrow burden (BMB) scores. Methods: Lyso-Gb1 and bone biomarkers, and BMB scores of 10 Gaucher type 1 (GD1) patients under enzyme therapy were prospectively evaluated. Results: Ten GD1 patients, aged between 4.5 and 40 (mean 23 ± 11 years), were included in the study. Four patients were homozygous for L444P/L444P, and six patients were compound heterozygous for N370S/R415H. We found positive correlations between pain and BMB scores with Lyso-Gb1 levels (r=0.889, p=0.001 and r=0.701, p=0.035, respectively). There were negative correlations between bone mineral density (BMD) of both the lumbar spine and femoral neck between Lyso-Gb1 levels (r=−0.929, p=0.001 and r=−0.893, p=0.007, respectively). Patients with L444P/L444P mutation had higher Lyso-Gb1 levels and BMB, pain scores and lower BMD measurements than patients with N370S/R415H (p=0.01, p=0.02, p=0.03, p=0.04, p=0.04, respectively). Conclusions: There was an apparent correlation between, Lyso-Gb1 levels, BMB scores and genotype in evaluating bone involvement in Gaucher patients.
- 17 March 2022
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 47 (4) , 457-463
Open AccessThe correlation between bone biomarkers, glucosylsphingosine levels, and molecular findings in Gaucher type 1 patients under enzyme therapy
Objectives: We aimed to determine the relationship of Lyso-Gb1 levels, bone biomarkers, and mutation findings with bone marrow burden (BMB) scores. Methods: Lyso-Gb1 and bone biomarkers, and BMB scores of 10 Gaucher type 1 (GD1) patients under enzyme therapy were prospectively evaluated. Results: Ten GD1 patients, aged between 4.5 and 40 (mean 23 ± 11 years), were included in the study. Four patients were homozygous for L444P/L444P, and six patients were compound heterozygous for N370S/R415H. We found positive correlations between pain and BMB scores with Lyso-Gb1 levels (r=0.889, p=0.001 and r=0.701, p=0.035, respectively). There were negative correlations between bone mineral density (BMD) of both the lumbar spine and femoral neck between Lyso-Gb1 levels (r=−0.929, p=0.001 and r=−0.893, p=0.007, respectively). Patients with L444P/L444P mutation had higher Lyso-Gb1 levels and BMB, pain scores and lower BMD measurements than patients with N370S/R415H (p=0.01, p=0.02, p=0.03, p=0.04, p=0.04, respectively). Conclusions: There was an apparent correlation between, Lyso-Gb1 levels, BMB scores and genotype in evaluating bone involvement in Gaucher patients.